MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to December 2019
Billion doses of treatment supplied to date
Million patient-years of treatment through MPP’s generic partners, from January 2012 to December 2019
KPMG calculated savings of USD1.44 billion and supply of 31.4 million patient-years of treatments through MPP’s generic partners from January 2012 to December 2019. Read the KPMG report.
Impact analysis, highlighting MPP’s sublicensees’ progress on treatments development, are available here.